Chat with us
Research Assistance
Online
  • Please enter your first name.

U.S. Orphan Drugs Market Size & Outlook, 2026-2033

The orphan drugs market in the United States is expected to reach a projected revenue of US$ 145.2 billion by 2033. A compound annual growth rate of 8.1% is expected of the United States orphan drugs market from 2026 to 2033.

  • Pharmaceuticals
    • Other Therapeutic Area Drugs
      • Orphan Drugs Market Outlook
Revenue, 2025 (US$B)
$78.4
Estimate, 2026 (US$B)
$84.2
Forecast, 2033 (US$B)
$145.2
CAGR, 2026 - 2033
8.1%
Prism AI by Grand View ResearchFree to try

Ask a question about the orphan drugs market

Every figure cited from GVR research

U.S. orphan drugs market outlook highlights

The U.S. orphan drugs market outlook generated a revenue of USD 78.4 billion in 2025 and is expected to reach USD 145.2 billion by 2033.

  • The market is expected to grow at a CAGR of 8.1% from 2026 to 2033.
  • In terms of segment, conventional biologics was the largest revenue generating drug type in 2025.
  • Cell Therapies is the most lucrative drug type segment registering the fastest growth during the forecast period.


Orphan Drugs Market Outlook data book summary

Market revenue in 2025USD 78.4 billion
Market revenue in 2033USD 145.2 billion
Growth rate8.1% (CAGR from 2026 to 2033)
Largest segmentConventional Biologics
Fastest growing segmentCell Therapies
Historical data2021 - 2024
Base year2025
Forecast period2026 - 2033
Quantitative unitsRevenue in USD billion
Market segmentationSmall Molecule Drugs, Conventional Biologics, Gene Therapies, Cell Therapies, Others Drug Type


Other key industry trends

  • In terms of revenue, U.S. accounted for 35.6% of the global orphan drugs market outlook in 2025.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In North America, U.S. orphan drugs market outlook is projected to lead the regional market in terms of revenue in 2033.
  • Canada is the fastest growing regional market in North America and is projected to reach USD 18.9 billion by 2033.

No credit card required*

Publish Date: Oct 16, 2026

Customize the Report

20% free customization

Include
Countries, segments, points
Tailor
To your product definition
Extend
Deeper competitor detail
Or
A fully bespoke study

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Orphan Drugs Market Companies

NameProfile# EmployeesHQWebsite
Johnson & JohnsonView profile 134,400One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933www.jnj.com
Pfizer IncView profile 88,00066 Hudson Boulevard East, New York, NY, United States, 10001-2192www.pfizer.com
Merck & Co IncView profile 72,000126 East Lincoln Avenue, Rahway, NJ, United States, 07065www.merck.com
AstraZeneca PLCView profile 89,9001 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AAwww.astrazeneca.com
Vertex Pharmaceuticals IncView profile 5,40050 Northern Avenue, Boston, MA, United States, 02210www.vrtx.com
Bristol Myers SquibbView profile ---
SanofiView profile ---
AmgenView profile ---
NovartisView profile ---

U.S. Orphan Drugs Market Outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Orphan Drugs Market Outlook will help companies and investors design strategic landscapes.


Conventional Biologics was the largest segment with a revenue share of 49.09% in 2025.

Horizon Databook has segmented the U.S. orphan drugs market based on small molecule drugs, conventional biologics, gene therapies, cell therapies, others drug type covering the revenue growth of each sub-segment from 2021 to 2033.


  • U.S. Orphan Drugs Market Drug Type Outlook (Revenue, USD Billion , 2021-2033)
    • Small Molecule Drugs
    • Conventional Biologics
    • Gene Therapies
    • Cell Therapies
    • Others Drug Type
  • U.S. Orphan Drugs Market Disease Type Outlook (Revenue, USD Billion , 2021-2033)
    • Rare Genetic & Inherited Disorders
    • Rare Cancers
    • Rare Congenital & Developmental Disorders
    • Rare Autoimmune & Immune-Mediated Disorders
    • Rare Infectious Diseases
    • Rare Acquired Disorders
    • Others Disease Type
  • U.S. Orphan Drugs Market Route of Administration Outlook (Revenue, USD Billion , 2021-2033)
    • Oral
    • Intravenous
    • Subcutaneous
    • Intramuscular
    • Intrathecal
    • Intraocular / Ophthalmic
    • Inhalation
    • Others Route of Administration
  • U.S. Orphan Drugs Market Distribution Channel Outlook (Revenue, USD Billion , 2021-2033)
    • Hospital Pharmacies
    • Specialty Pharmacies
    • Retail Pharmacies
    • Mail-Order / Online Pharmacies
    • Others Distribution Channel

Reasons to subscribe to Orphan Drugs Market Outlook databook

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Orphan Drugs Market Outlook databook

  • Our clientele includes a mix of Orphan Drugs Market Outlook companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Orphan Drugs Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Orphan Drugs Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.

U.S. Orphan Drugs Market, 2021-2033 (US$B)

No Access Stack Chart

U.S. orphan drugs market statistics, by drug type 2021 - 2033 (USD Billion)

No Access Pie Chart

U.S. orphan drugs market statistics, by drug type 2021 - 2033 (USD Billion)

No Access

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more